



## **CanAm Bioresearch Inc. and EpiTherapeutics ApS Announce Medicinal Chemistry Research Agreement**

**Winnipeg, Manitoba – June 23, 2011** - CanAm Bioresearch Inc. and EpiTherapeutics ApS (Denmark) are pleased to announce the signing of a medicinal chemistry research services agreement for the development of novel innovative anti-cancer drugs.

"We are very pleased to enter into a formalized drug discovery collaboration with CanAm, after working with their team for the past several months," stated Lars-Ole Gerlach, EVP R&D EpiTherapeutics ApS. CanAm has significant expertise and experience in new drug discovery medicinal chemistry and a proven track record of delivering results. We look forward to a fruitful collaboration with the aim of developing novel anti-cancer drugs within the promising new area of epigenetics."

CanAm is a well-established contract research organization specializing in pre-clinical discovery and development, particularly focused on medicinal chemistry. "This collaboration further validates CanAm's approach and expertise in drug discovery chemistry," said Mr. Marcus Enns, President, CanAm Bioresearch Inc. "We are excited about partnering with EpiTherapeutics and look forward to delivering novel candidate drugs."

### **About EpiTherapeutics ApS**

EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen. EpiTherapeutics has a strong investor base highlighted by founding investors Novo A/S and SEED Capital Denmark and joined by Lundbeckfond Ventures, OSI Pharmaceuticals and Merck Serono Ventures.

### **About CanAm Bioresearch Inc.**

CanAm is a privately held company located in Winnipeg, Canada that specializes in pre-clinical contract research services. In business for more than 10 years, CanAm provides bioanalytical, pharmacokinetic, pharmacology, and custom chemical synthesis services within its fully equipped research facility. The Company's team of experienced scientists can assist in designing the best strategy to suit any drug discovery need.

### **For more information, please contact:**

EpiTherapeutics ApS.

Lars-Ole Gerlach, Ph.D.  
Executive Vice President R&D  
[log@epitherapeutics.com](mailto:log@epitherapeutics.com)  
[www.epitherapeutics.com](http://www.epitherapeutics.com)

CanAm Bioresearch Inc.

Marcus Enns  
President  
204.477.7595  
[menns@canambioresearch.com](mailto:menns@canambioresearch.com)  
[www.canambioresearch.com](http://www.canambioresearch.com)